US News Covid-19: the European Medicines Agency in favor of antibody treatment
The European Union wants a reform of the WTO and green its trade policy
© FRANCISCO SECO / AFP The Vice-President of the European Commission, Valdis Dombrovskis, on February 18 in Brussels. The European Commission has defined its new trade policy to “fully support ecological and digital transformations”. She also calls for reform of the World Trade Organization.
The European Agency in charge of drug regulation gave a favorable opinion on Friday for the deployment of antibody treatment from the American company Regeneron. This is the drug that was used to treat, in 2020, former US President Donald Trump.
Theto recover from last fall will soon be available to Europeans. The European Medicines Agency (EMA) in fact issued, Friday, February 26, a favorable opinion for the provisional use of antibody treatment from the American company Regeneron.
Covid-19: Macron gives himself 8 to 10 days to relax or tighten the constraints
The Elysée would give himself 8 to 10 days to decide on the next strategy to be adopted in the face of the Covid-19 epidemic. © Romain Gaillard / Pool / Bestimage Release the pressure or tighten the constraints? The Elysée is giving itself 8 to 10 days to decide in the face of the Covid-19 epidemic, the economic and health consequences of which continue to rage.
In, this drug manages to reduce the amount of virus present in the back of the nose and throat of patients who test positive for Covid-19.
The European medicines regulator claims to have concluded that REGN-COV2 can be used as a treatment in patients "who do not require supplemental oxygen and who do not present a high risk of progressing to a severe form of Covid-19 . "
REGN-COV2 is a combination of casirivimab and imdevimab, two monoclonal antibodies given to patients by infusion, the EMA said.
Manufactured in the laboratory, these synthetic antibodies mimic the action of antibodies naturally produced by the immune system in the event of infection.
Casirivimab and imdevimab, were designed to attack the S protein, which forms the tiny spikes on the surface of the virus, the EMA said. The antibody clings to these spikes, preventing it from attaching itself to the human cell to infect it.
Covid-19: England aims for a return to normal at the end of June
British Prime Minister Boris Johnson said on Monday to aim for a return to almost normal for the summer, presenting a deconfinement strategy that he wants " prudent "but" irreversible "and which will begin with the reopening of schools in early March.
An ongoing review of the two antibodies, which began on February 1, was "underway," the European regulator said, adding that "once finalized it will form the basis for a marketing authorization for the 'EU for this combination ".
France orders thousands of treatments
The announcement follows the Amsterdam-based EMA's monthly meeting, where it also recommended approval of six other drugs, including the first oral treatment for patients with certain types of spinal muscular atrophy, a rare and often fatal genetic disease that causes muscle weakness and progressive loss of motor skills.
The US Medicines Agency (FDA) gave emergency clearance for the use of REGN-COV2 in November.
France also announced on Thursday that it had distributed thousands of monoclonal antibody treatments to hospitals.
The EMA, however, did not make an announcement on Friday on approval of the Covid-19 vaccine from Johnson & Johnson, which earlier this month applied for marketing authorization for the 'European Union.
An American panel of independent experts met on Friday to consider a possible green light for the deployment of Johnson & Johnson's vaccine on American soil.
The European Medicines Agency has so far authorized three vaccines in the EU: those from Pfizer / BioNTech, Moderna and AstraZeneca.
Covid-19: Italy blocks the export of AstraZeneca vaccines to Australia .
© Supplied by Le Parisien Le Parisien This is a major first for the EU. Italy has blocked the export to Australia of doses of AstraZeneca vaccine produced on European soil, the Italian government said Thursday. Rome communicated its decision on February 26 to the European Commission, which did not object. The Foreign Office said in a statement that the refusal to export involved 250,700 doses from the Swedish-British laboratory.